Guidance Offers IDE Tips For Devices Targeting Brain Disease Progression
This article was originally published in The Gray Sheet
FDA issued a draft guidance to help device-makers conduct clinical trials for products designed to slow the progress of neurological conditions. One challenge highlighted by the agency is that changes to biomarkers measured in a study may not line up easily with disease progression.
You may also be interested in...
The US agency finalized its guidance on IDEs for devices intended to treat the cause or progression, rather than just the symptoms, of neurological conditions like Alzheimer's.
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.